ADC Therapeutics Announces ZYNLONTA® Updates in Japan
PR Newswire•29/10/2026•07:30 ET
0
Key Highlights
- ➤Japan filing submitted for ZYNLONTA in relapsed/refractory DLBCL after two systemic therapies
- ➤Japanese Phase 2 overall response rate reached 58.1%, with 41.9% complete responses
- ➤Tanabe Pharma sublicensed Japanese commercialization to Nippon Shinyaku
- ➤ADC Therapeutics expects regulatory and commercial milestones from Japan partnership
Expert Statements
Ameet Mallik, Chief Executive Officer of ADC Therapeutics
“This is a significant step forward in our efforts to expand ZYNLONTA's global reach to bring this important treatment option to more patients with B-cell malignancies.”
Ameet Mallik, Chief Executive Officer of ADC Therapeutics
“Japan represents a meaningful opportunity for ZYNLONTA, and we're encouraged by the progress our partners are making toward its potential introduction in this market.”
Ameet Mallik, Chief Executive Officer of ADC Therapeutics
“We look forward to building on this momentum as ZYNLONTA advances toward its next regulatory and commercial milestones.”
ADC Therapeutics Announces ZYNLONTA® Updates in Japan PR Newswire
Licensing partner, Tanabe Pharma, filed for Japanese approval of ZYNLONTA (MT-2111) for relapsed or refractory DLBCL based on encouraging Japanese Phase 1/2 clinical results
Get started
Create a free account to read the full story.